Hepatocellular carcinoma development in a patient with HCV infection after eradication with direct-acting antiviral agents

WCRJ 2017; 4 (1): e833
DOI: 10.32113/wcrj_20173_833

  Topic: Virus and cancer     Category:

Fiore V.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Vidili G.
Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Bagella P.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Lobrano G.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Muredda A. A.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Caruana G.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Babudieri S.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Madeddu G.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
giordano@uniss.it Close

Abstract

Hepatitis C virus (HCV) treatment with Interferon (IFN)-free direct-acting antiviral agents (DAAs) showed high rates of success, leading to substantial changes in this field. However, limited data are available about the evolution of liver disease after HCV eradication. Recently, published studies on the recurrence of hepatocellular carcinoma (HCC) after HCV treatment raised questions on the real benefit of treatment of patients with advanced fibrosis or cirrhosis.

We report a case of a 45-years-old cirrhotic patient successfully treated with DAAs who developed an HCC after HCV eradication.

Hepatitis C virus (HCV) treatment with Interferon (IFN)-free direct-acting antiviral agents (DAAs) showed high rates of success, leading to substantial changes in this field. However, limited data are available about the evolution of liver disease after HCV eradication. Recently, published studies on the recurrence of hepatocellular carcinoma (HCC) after HCV treatment raised questions on the real benefit of treatment of patients with advanced fibrosis or cirrhosis.

We report a case of a 45-years-old cirrhotic patient successfully treated with DAAs who developed an HCC after HCV eradication.

Free PDF Download

To cite this article

Fiore V.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Vidili G.
Unit of Internal Medicine, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Bagella P.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Lobrano G.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Muredda A. A.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Caruana G.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Babudieri S.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy Close
, Madeddu G.
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
giordano@uniss.it Close
Hepatocellular carcinoma development in a patient with HCV infection after eradication with direct-acting antiviral agents

WCRJ 2017; 4 (1): e833
DOI: 10.32113/wcrj_20173_833

Publication History

Submission date: 23 Feb 2017

Revised on: 04 Mar 2017

Accepted on: 22 Mar 2017

Published online: 30 Mar 2017